A View LCS vs ClearRead CT
AI Verdict
Choose A View LCS if…
Choose AVIEW LCS if your institution requires a highly comprehensive AI solution for thoracic CT analysis from a single low-dose scan, encompassing detailed lung cancer screening, emphysema quantification, and advanced coronary artery calcification scoring with major artery segmentation. This tool is ideal for generating automated, multi-parameter reports and leveraging CT kernel conversion AI for diverse imaging protocols.
View A View LCS →Choose ClearRead CT if…
Choose ClearRead CT if your priority is to significantly enhance pulmonary nodule detection accuracy and streamline radiology workflows by reducing reading times. This tool is particularly well-suited for leveraging patented vessel suppression technology to improve clarity and for automated nodule tracking and comparison to prior exams, leading to more confident and efficient diagnoses.
View ClearRead CT →When choosing between AVIEW LCS and ClearRead CT, physicians should consider their primary focus in thoracic CT analysis. AVIEW LCS excels in comprehensive thoracic CT analysis from a single low-dose CT scan, offering detailed lung cancer screening, emphysema quantification, and coronary artery calcification detection. Its strengths lie in automated nodule detection and classification, 3D volume quantification, Lung-RADS scoring, and advanced emphysema analysis. It also provides segmentation of major coronary arteries and CT kernel conversion AI technology, making it suitable for practices requiring a broad, integrated assessment of thoracic health.
In contrast, ClearRead CT specializes in enhancing pulmonary nodule detection and coronary artery calcification analysis with a focus on improving diagnostic accuracy and reducing reading times. Its key differentiator is patented vessel suppression technology, which aids in more confident nodule detection. ClearRead CT also offers automated nodule tracking and comparison to prior exams, and it emphasizes seamless PACS integration. The practical difference lies in AVIEW LCS’s broader, multi-faceted analytical capabilities versus ClearRead CT’s specialized focus on optimizing nodule detection and workflow efficiency through its unique vessel suppression.
Therefore, a physician prioritizing a comprehensive, all-in-one thoracic CT analysis platform with advanced quantification for lung cancer screening and emphysema should lean towards AVIEW LCS. Conversely, a physician whose primary goal is to enhance the accuracy and speed of pulmonary nodule detection, particularly benefiting from advanced vessel suppression technology and streamlined workflow, would find ClearRead CT to be the more appropriate choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | A View LCS | ClearRead CT |
|---|---|---|
| Pricing | Contact for quote | Contact for pricing |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | On-premise (stand-alone server, virtual machine) and Cloud |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ClearRead CTBoth tools emphasize seamless PACS integration and automated reporting. However, ClearRead CT explicitly highlights 'concurrent reading' and provides specific metrics for reduced reading time (up to 36%) and improved detection accuracy without compromising workflow, indicating superior efficiency and user experience.
Clinical Value
A View LCSWhile both are FDA-cleared and offer strong clinical value in nodule detection and CAC scoring, AVIEW LCS provides a broader 'comprehensive thoracic CT analysis' including emphysema quantification and detailed segmentation of major coronary arteries, which ClearRead CT does not explicitly highlight. AVIEW LCS has also demonstrated its capability to act as a first-line reader, potentially offering a more significant impact on radiologist workload and screening program efficiency.
Pricing & Value
TieBoth tools require direct contact for pricing, making a direct comparison of their cost structures impossible. While ClearRead CT has some third-party analysis on potential cost savings, AVIEW LCS also offers flexible licensing models, suggesting both aim to provide value tailored to institutional needs.
Enterprise Readiness
A View LCSWhile both offer robust deployment options and PACS integration, AVIEW LCS explicitly states 'has_baa': '1' and 'hipaa_compliant': '1', along with GDPR and UKCA certifications, providing clearer and more comprehensive compliance assurances compared to ClearRead CT's 'likely' claims in the JSON. AVIEW LCS also lists a broader range of deployment flexibility.
Innovation
ClearRead CTClearRead CT's 'Patented Vessel Suppression' technology is a highly innovative and clinically impactful feature, explicitly designed to improve nodule conspicuity by removing obscuring structures. Furthermore, its distinction as the 'first FDA-cleared device to support concurrent reading' and demonstrate improved reader accuracy and reading time highlights its pioneering role in workflow integration and clinical efficacy.
Support & Docs
A View LCSAVIEW LCS explicitly mentions dedicated onboarding support, including technical integration, workflow configuration, and user training, along with local technical and clinical support through partners. While ClearRead CT provides a customer hotline and user manuals, one source indicates a potential lack of publicly available technical documentation, suggesting AVIEW LCS offers more transparent and comprehensive support and documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | A View LCS | ClearRead CT |
|---|---|---|
| Name | A View LCS | ClearRead CT |
| Company | Coreline Soft Co. | RIVERAIN TECHNOLOGIES |
| Key Features (Lung Nodule) | Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Lung-RADS scoring and reporting | Pulmonary Nodule Detection (solid, part-solid, ground glass), Nodule Characterization and Measurement (volume, diameter, location, type, depth), Automated Nodule Tracking and Comparison to Prior Exams |
| Key Features (Cardiac) | Coronary Artery Calcium (CAC) scoring (Agatston, volume, mass), Segmentation of major coronary arteries | Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs) |
| Key Features (Other) | Emphysema analysis and quantification (LAA), Automated comprehensive report generation (PDF, DICOM PDF, SR), CT kernel conversion AI technology | Patented Vessel Suppression (Clear Visual Intelligence), Reduced Reading Time (up to 36%), Improved Detection Accuracy (29% reduction in missed actionable nodules), Seamless PACS Integration / Vendor-neutral processing |
Videos
Demos, reviews, and walkthroughs featuring A View LCS and ClearRead CT.